BioSpace News Archive

GPCR Therapeutics, Inc., a clinical stage international biopharmaceutical company with an innovative approach to developing cancer therapeutics based on targeting G Protein Coupled Receptors pairs, announces publication of a research paper in PLOS ONE.

Ocean Biomedical, Inc. announced that its joint venture partner Virion Therapeutics, LLC, a clinical-stage biotechnology company developing novel T cell-based immunotherapies, dosed its first patients in a Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus infection.

Virion Therapeutics, LLC and its Joint Venture partner, Ocean Biomedical, Inc., announced that the first patients have been dosed in the Phase 1b clinical trial of its investigational VRON-0200 immunotherapy, which is being evaluated as a functional cure for patients with chronic Hepatitis B virus infection.

Boston Scientific Corporation generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational1 basis and 10.2 percent on an organic2 basis, all compared to the prior year period.

TELA Bio, Inc. announced that the Company will report third quarter 2023 financial results on Thursday, November 9, 2023.

BioCryst Pharmaceuticals, Inc. announced the enrollment of the first patient in a proof-of-concept clinical trial evaluating BCX10013, a potential once-daily, oral Factor D inhibitor for the treatment of complement-mediated diseases.

Orchard Therapeutics, a global gene therapy leader, announced a range of interim clinical outcomes, in addition to the previously reported neurological and skeletal results, from the company’s ongoing proof-of-concept study of OTL-203, a hematopoietic stem cell gene therapy in development for the treatment of the Hurler subtype of mucopolysaccharidosis type I.

Generation Bio Co. announced that it has reached two significant achievements through in vivo studies, including results generated as part of its collaboration with Moderna, Inc. First, Generation Bio has shown highly selective T cell targeting in vivo with its cell-targeted LNP platform in a humanized mouse model.

Alimera Sciences, Inc. today announced financial results for the third quarter of 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Chemomab Therapeutics Ltd. today announced the company will present at major U.S. scientific conferences in November.